Group items tagged

The launch of Protease Inhibitors (PIs) accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations. Freedom from IFN, treating all genotypes and vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of USD 230 mn followed by GILD buying VRUS for USD 11 bn, Bristol-Myers Squibb (BMY) acquiring Inhibitex for USD 2.5 bn, VRTX acquiring Virochem in 2009 for USD 375 mn, In-licensed Alios VX-135 in 2012 for total of USD 775 mn and Abbott in-licensed Enantas ABT-450 for total of USD 310 mn.

The German chronic heart failure (CHF) therapeutics market was worth approximately USD 484.7 million in 2012, with a projected compound annual growth rate (CAGR) of 2.4%, to reach a total of USD 614.8 million in 2022. The launch of Novartis' novel combination drug, LCZ-696 in 2015 will mark the first entrance of a novel branded CHF drug in the past five years, boosting the overall market size considerably till 2022.

According to diagnostic ultrasound imaging market forecasts, the global disease incidence is expected to rise and an early diagnosis of disease is the foundation for increasing survival rates. Diagnostic ultrasound imaging is the most widely used technique to achieve early detection and clinical assessment of adult and pediatric patients alike, making it a cornerstone of disease control. In the diagnostic ultrasound imaging market landscape GE Healthcare currently dominates the global diagnostic ultrasound market.

Consumers increasing saving motivations since the recession has led to five consecutive years of moderate growth in the retail savings industry, despite low interest rates, high unemployment and lower wages.

Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.

The global vitamin D testing market is expected to grow at a CAGR of 32.36% over 2013 to 2018. One of the key factors contributing to this market growth is the increase in aging and chronically ill populations worldwide. This market has also been witnessing the increase in product approvals.

The global touchless sensing equipment market is anticipated to grow at a CAGR of 32.2% over 2012 to 2016. The global touchless sensing equipment market has also been witnessing rapid technological advancement. However, touchless sensing equipment is not 100% accurate which could pose a challenge to the growth of this market. Growing need for high-level security in the government sector is set to drive the global touchless sensing equipment market.

The global femtocell market is expected to grow in the U.S. and it is estimated to be the fastest growing market among all other markets during analysis period. Developed countries such as Europe, Australia, and U.K. have a higher adoption rate of femtocell technology as compared to developing countries.

After getting such a huge response. We are offering 50% off by using code VTCGED50. Limited Offer.. Act Now-> http://cheapgenericeddrug.com Valentines Day offer! 50% off on all products at cheapgenericeddrug.com. Impotency issues are no more a nightmare! Offer limited, act now!